Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives

Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line for metastatic disease and in neoadjuvant setting,...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenza, Carmine, Rizzo, Graziella, Passalacqua, Maria Ilenia, Boldrini, Laura, Corti, Chiara, Trapani, Dario, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893403/
https://www.ncbi.nlm.nih.gov/pubmed/36743524
http://dx.doi.org/10.1177/17588359221146129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893403/
https://www.ncbi.nlm.nih.gov/pubmed/36743524
http://dx.doi.org/10.1177/17588359221146129

Ejemplares similares